Legacy PhRMA Studies

Keyword:

Company:

Merck studies
Schering-Plough/Organon studies
All studies

LEGACY STUDY SEARCH RESULTS

77 studies found for your search request: Merck studies

CANCIDAS® (caspofungin acetate) (MK-0991-033)
Condition: Pharmacokinetics
Phase: Phase II
Company: Merck

CRIXIVAN® (indinavir sulfate) (MK-0639-035-50)
Condition: AIDS
Phase: Phase II
Company: Merck

CRIXIVAN® (indinavir sulfate) (MK-0639-112)
Condition: AIDS
ClinicalTrials.gov Identifier: NCT00541463 (view full study on clinicaltrials.gov)
Phase: Phase II
Company: Merck

EMEND® (aprepitant) (MK-0869-071)
Condition: Cancer, Chemotherapy-Related Conditions
ClinicalTrials.gov Identifier: NCT00092183 (view full study on clinicaltrials.gov)
Phase: Phase IV
Company: Merck

EMEND® (aprepitant) (MK-0869-071-10)
Condition: Cancer, Chemotherapy-Related Conditions
ClinicalTrials.gov Identifier: NCT00092196 (view full study on clinicaltrials.gov)
Phase: Phase IV
Company: Merck

Copyright © 2024 · Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. · This site is intended only for residents of the United States.
Cookie Preferences Privacy Terms of Use Consumer Health Data Privacy Policy Your Privacy Choices Accessibility U.S. Corporate Site